<DOC>
	<DOC>NCT00117143</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit dosing (Âµg) in thrombocytopenic subjects with ITP.</brief_summary>
	<brief_title>Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Greater than or equal to 3 months history if ITP, regardless of splenectomy status, and completion of at least 1 prior treatment for ITP 2 of 3 pretreatment platelet counts that were less than 30 x 10^9/L (if not currently on ITP therapy) or less than 50 x 10^9/L (if currently receiving corticosteroids for ITP therapy) Ability to give informed consent Known history of arterial thrombosis, active malignancy, or bone marrow stem cell disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>